Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00002300 · ClinicalTrials.gov registry record · Phase 2

A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition

A Phase 2 study of HIV Infections and Cachexia, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 2
Development phase
15
Study locations

NCT00002300 is a Phase 2 study of HIV Infections and Cachexia that has completed, run by Bristol-Myers Squibb. The trial reports 15 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00002300, a Phase 2 study of HIV Infections and Cachexia, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 2
Development phase
15
Study locations

Study Summary

To compare the effects of megestrol acetate and placebo on body weight, anorexia, cachexia, calorie intake, and nutritional parameters of patients with a confirmed diagnosis of AIDS. To characterize dose response in relation to weight gain. To determine whether megestrol acetate relative to placebo improves the perception of well-being among AIDS patients with cachexia. To evaluate megestrol acetate's effect on immune function via skin test reactivity, T4/T8 ratio, and total lymphocytes.

Interventions

  • DRUG Megestrol acetate

Study Locations (15)

New York

  • Albany Med College / AIDS Treatment Ctr - Albany
  • Community Research Initiative on AIDS - New York
  • Saint Vincent's Hosp and Med Ctr - New York
  • Mem Sloan - Kettering Cancer Ctr - New York

California

  • Dr NS Tchekmedyian - Long Beach
  • Dr Stephen J Gabin Jr - Los Angeles
  • Eisenhower Med Ctr - Rancho Mirage

District of Columbia

  • George Washington Univ Med Ctr - Washington D.C.
  • Veterans Administration Med Ctr - Washington D.C.

Alabama

  • Birmingham Veterans Administration Med Ctr / Univ of Alabama - Birmingham

Colorado

  • Denver Public Health Dept - Denver

Florida

  • Miami Veterans Administration Med Ctr - Miami

Illinois

  • Northwestern Univ Med School - Chicago

Pennsylvania

  • Univ of Pennsylvania - Philadelphia

Trial Details

FieldValue
Phase Phase 2

Sponsor

Bristol-Myers Squibb

1,025 total trials

What the Registry Record Tells You About NCT00002300

The ClinicalTrials.gov registry entry for NCT00002300 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Megestrol acetate is the first listed.

NCT00002300 reports 15 study locations spanning 9 distinct geographic areas - top geographies include New York, California, District of Columbia.

Frequently Asked Questions

What is clinical trial NCT00002300 about?

NCT00002300 is a clinical study titled "A Study of Different Doses of Megestrol Acetate in Patients With AIDS Who Have Anorexia and Malnutrition". To compare the effects of megestrol acetate and placebo on body weight, anorexia, cachexia, calorie intake, and nutritional parameters of patients with a confirmed diagnosis of AIDS. To characterize dose response in relation to weight gain. To determine whether megestrol acetate relative to placebo ...

What is the current status of trial NCT00002300?

This trial is currently completed. It is a Phase 2 study.

What conditions does trial NCT00002300 study?

This clinical trial studies the following conditions: HIV Infections, Cachexia, Anorexia.

What interventions are being tested in trial NCT00002300?

The interventions under investigation include: Megestrol acetate (DRUG).

Who is sponsoring clinical trial NCT00002300?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00002300 being conducted?

This trial has 15 study locations across Alabama, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.